GenFleet Therapeutics (Shanghai) Inc. (GENFLEET-B) disclosed a Next Day Disclosure Return detailing the on-market repurchase of 50,000 H shares on 15 September 2026. The purchase, executed on the Hong Kong Stock Exchange, was completed at prices ranging from HKD 25.80 to HKD 26.16 per share, with a volume-weighted average repurchase price of HKD 25.91. Aggregate consideration amounted to HKD 1.30 million.

Following the transaction, the company’s issued share capital (excluding treasury shares) declined by 0.014% to 351.31 million shares, down from 351.36 million shares as of 10 September 2026. GenFleet’s treasury-share balance rose to 321,000 shares, while total issued shares remained unchanged at 351.63 million due to the shares being held in treasury.

The repurchase formed part of the mandate approved by shareholders on 11 May 2026, which authorises the company to repurchase up to 37.04 million shares. Cumulative buybacks under this mandate now stand at 321,000 shares, equivalent to 0.087% of the issued share base at the mandate date. A moratorium on new share issues or treasury-share disposals is in effect until 15 October 2026 in line with Hong Kong listing rules.

Management confirmed that the repurchase complied with all applicable regulatory requirements, with full payment for the shares and proper filings completed.